Article
12 Dec 2025
Infringement By Common Design Found In Canadian Case
Beverley Moore
Popular Topics
Intellectual Property
Beverley Moore’s articles from Borden Ladner Gervais LLP are most popular:
- with Finance and Tax Executives
- in Africa, Europe and United States
AUTHORS CONTENT
Article
10 Nov 2025
Narrow Issues Of Claim Construction, Double Patenting, And Costs Determined On Appeal
Article
28 Jul 2025
Patented Medicine Prices Review Board Publishes New Guidelines For PMPRB Staff: Finally, Some Guidance For Patentees
Article
10 Jul 2025
Can One Infringe An Apparatus Patent With Mere Plans Or Drawings? The SCC's Denial Of Leave Confirms That The Answer Is No
Article
31 Jan 2025
Patent Is NOT Listed On Patent Register When Form IV Is Filed; Only When Minister Determines It Is Eligible
Article
19 Dec 2024
Patent Term Adjustment In Canada: More Of A Unicorn Than A Safety Net
Article
10 Dec 2024
The FCA Concludes PMPRB Decision Re Differin® Exceeded The Board's Jurisdiction
Article
24 Nov 2023
The Patented Medicines Prices Review Board Is Consulting On New Guidelines
Article
01 Nov 2023
Active Consultation: Amendments To The Copyright Act Relating To Generative Artificial Intelligence
Article
09 Oct 2023
To Intervene Or Not To Intervene Before The Federal Courts
Article
07 Aug 2023
Patent Term Restoration In Canada
Article
07 Aug 2023
Much Anticipated FCA Decision In Benjamin Moore Removes Prescriptive Test Ordered By FC
Article
07 Jun 2023
Canada's New Excess Claims Fees Vs Double Patenting
Article
07 Jun 2023
Accounting Of Profits Remedy For Patent Infringement In Canada
Article
12 May 2023
Patent Term Adjustment Is Coming To Canada
Article
08 May 2023
Medical Device Litigation Trends In Canada And The U.S. (Video)
Article
24 Nov 2022
SCC Provides Clarity On Accounting Of Profits Remedy In Patent Infringement
Article
04 Oct 2022
Navigating New Excess Claims Fees And Double Patenting Risk In Canadian Patent Prosecution: The Devil And The Deep Blue Sea
Article
08 Sep 2022
NOC Regulations Do Not Apply To Biosimilars When Reference Products Are Not Marketed
Article
11 Jul 2022
Innovative Pharmaceutical Companies Need To Be Aware Of The Competition Act
